Prognostic significance of CD83 positive, mature dendritic cells in the gallbladder carcinoma
- PMID: 16012714
Prognostic significance of CD83 positive, mature dendritic cells in the gallbladder carcinoma
Abstract
Dendritic cells (DCs) are very potent antigen-presenting cells that play an essential role in the primary immune response to carcinoma. Tumor-infiltrating DCs have been found to be clinically significant in many human malignancies such as colon, stomach, lung, breast and hepatic carcinoma. However, clinical significance of activated and/or immature DCs in gallbladder carcinoma has not been reported yet. Thus, we immunohistochemically evaluated CD83+ DCs and CD1a+ DCs of cancerous and peritumoral area in 29 cases of resected gallbladder. In the results, CD83(+) DCs were significantly fewer in cancerous area than that in peritumoral area (1.55/hpf vs. 4.26/hpf, p=0.0047), but the numbers of CD1a(+) DCs did not differ (p=0.075). In addition, we defined a CD83 index as CD83(+) DCs/(CD83(+) DCs plus CD1a(+) DCs), and analyzed the relationship between CD83 index and clinicopathological factors. The group with a higher CD83 index (index >0.316) showed significantly better prognosis than the group with a lower CD83 index (index < or =0.316) in cancerous and peritumoral areas. In conclusion, we suggest the importance of tumor-infiltrating CD83(+) DCs as a useful prognostic factor for patients with gallbladder carcinoma.
Similar articles
-
Prognostic significance of CD83 positive tumor-infiltrating dendritic cells and expression of TGF-beta 1 in human gastric cancer.Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1834-40. doi: 10.5754/hge10320. Hepatogastroenterology. 2011. PMID: 22086706
-
Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas.Int J Cancer. 2003 Mar 10;104(1):92-7. doi: 10.1002/ijc.10915. Int J Cancer. 2003. PMID: 12532424
-
Prognostic value of CD83-positive mature dendritic cells and their relation to vascular endothelial growth factor in advanced human gastric cancer.Oncol Rep. 2005 Aug;14(2):369-75. Oncol Rep. 2005. PMID: 16012717
-
CD83: a regulatory molecule of the immune system with great potential for therapeutic application.J Med Dent Sci. 2006 Jun;53(2):85-91. J Med Dent Sci. 2006. PMID: 16913569 Review.
-
CD1a and antitumour immune response.Immunol Lett. 2004 Aug 15;95(1):1-4. doi: 10.1016/j.imlet.2004.05.006. Immunol Lett. 2004. PMID: 15325791 Review.
Cited by
-
CD83 antigen expression and its role in the progression of systemic malignancies.Sao Paulo Med J. 2013;131(2):137. doi: 10.1590/s1516-31802013000100027. Sao Paulo Med J. 2013. PMID: 23798069 Free PMC article. No abstract available.
-
Intratumoral immunization: a new paradigm for cancer therapy.Clin Cancer Res. 2014 Apr 1;20(7):1747-56. doi: 10.1158/1078-0432.CCR-13-2116. Clin Cancer Res. 2014. PMID: 24691639 Free PMC article.
-
CD83, a Novel MAPK Signaling Pathway Interactor, Determines Ovarian Cancer Cell Fate.Cancers (Basel). 2020 Aug 13;12(8):2269. doi: 10.3390/cancers12082269. Cancers (Basel). 2020. PMID: 32823589 Free PMC article.
-
CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients.Breast Cancer. 2022 Jul;29(4):618-635. doi: 10.1007/s12282-022-01336-2. Epub 2022 Feb 8. Breast Cancer. 2022. PMID: 35137329
-
CD83(+) dendritic cells and Foxp3(+) regulatory T cells in primary lesions and regional lymph nodes are inversely correlated with prognosis of gastric cancer.Gastric Cancer. 2012 Apr;15(2):144-53. doi: 10.1007/s10120-011-0090-9. Epub 2011 Nov 15. Gastric Cancer. 2012. PMID: 22083420
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical